Full Press Release Details
Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA
Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch
WASHINGTON, December 16, 2022 /PRNewswire/ Vanda
Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ ANDA litigation ruling.
On December 14, 2022, Vanda appealed the December 13th decision of the United States District
Court for the District of Delaware in the HETLIOZ ANDA litigation to the United States Court of Appeals for the Federal Circuit and requested an injunction prohibiting market entry by Teva
Pharmaceuticals USA, Inc. (Teva) and Apotex Inc. (Apotex) while the appeal is pending. Today, the Court granted a temporary injunction to prohibit market entry by Teva and Apotex until at least January 6, 2023 while the Court considers
Vanda s pending motion for an injunction that would extend until the Court decides the appeal.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical
For full U.S. Prescribing Information for HETLIOZ and HETLIOZ LQ , including indication and Important Safety Information, visit www.hetlioz.com.
Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.